TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28071011

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LC)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Isocaloric diet plus metformin (IM)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 77
Study: 23941272

Group type: EXPERIMENTAL
Intervention: Priming randomness
Number of subjects: 134

Group type: COMPARATOR
Intervention: Priming negativity
Number of subjects: 134

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 134
Study: 22282104

Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) destination therapy (DT)
Number of subjects: 414
Study: 20034967

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 20
Study: 18355402

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy plus systemic therapy (cyclophosphamide, methotrexate, and fluorouracil for premenopausal women; tamoxifen for postmenopausal women)
Number of subjects: 3083

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 3083
Study: 15845701

Group type: EXPERIMENTAL
Intervention: Red cells stored <8 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard red cells
Number of subjects: 66
Study: 12578439

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of methylphenidate (3 times daily)
Number of subjects: 0
Study: 10561294

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast (XRT group)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No further treatment (non‐XRT group)
Number of subjects: 381
Study: 8961310

Group type: EXPERIMENTAL
Intervention: Random practice condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blocked-Random practice condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blocked practice condition
Number of subjects: 30
Study: 1762298

Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine ointment (T)
Number of subjects: 129
Study: 7050047

Group type: EXPERIMENTAL
Intervention: Therapeutic irradiation (175 rad every other day to a total of 525 rad)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 64
Study: 31869451

Group type: EXPERIMENTAL
Intervention: High-dose gabapentin (2700 mg daily) with standard care (hydrocodone and/or acetaminophen progressing to fentanyl as needed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose gabapentin (900 mg daily) with methadone
Number of subjects: 60
Study: 30343354

Group type: EXPERIMENTAL
Intervention: Oral saffron supplementation (20 mg/day) for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral saffron supplementation (20 mg/day) for 3 months among participants on AREDS supplements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 100
Study: 28803704

Group type: EXPERIMENTAL
Intervention: Graded activity exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Physiotherapy-based exercises
Number of subjects: 66
Study: 26813634

Group type: EXPERIMENTAL
Intervention: Running with a familiar peer
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Running with an unfamiliar peer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Running alone
Number of subjects: 24
Study: 24788102

Group type: EXPERIMENTAL
Intervention: Racotumomab-alum (5 immunizations every 2 weeks and re-immunizations every 4 weeks)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 21594233

Group type: EXPERIMENTAL
Intervention: Silane/adhesive/Variolink II
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zirconia primer/Multilink Automix
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thermocycling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-glazed groups
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glazed groups
Number of subjects: 80
Study: 19292787

Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both PUVA modalities
Number of subjects: 29
Study: 17686343

Group type: EXPERIMENTAL
Intervention: Cytotoxic monoclonal antibodies (MAbs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath‐1H®)
Number of subjects: 0
Study: 16043407

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 50 mg bid
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 51
Study: 11589868

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol (Cosopt)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 15
Study: 9727377

Group type: EXPERIMENTAL
Intervention: Plasma pentosidine levels in diabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma pentosidine levels in patients with normal renal function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of ischemic heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0
Study: 8071837

Group type: EXPERIMENTAL
Intervention: BOF-4272 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BOF-4272 200 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BOF-4272 400 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BOF-4272 200 mg (multiple-dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (single-dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (multiple-dose)
Number of subjects: 14
Study: 2485283

Group type: EXPERIMENTAL
Intervention: Relapse prevention (RP) program emphasizing cognitive‐behavioral coping skills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad spectrum (BS) program emphasizing behavioral skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 30937510

Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy (NECT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 170
Study: 25349051

Group type: EXPERIMENTAL
Intervention: Peer education intervention in two sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 60
Study: 25692310

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD via Respimat®
Number of subjects: 3104

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD via Respimat®
Number of subjects: 3104

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg BID via Aerolizer®
Number of subjects: 3104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3104
Study: 24153053

Group type: EXPERIMENTAL
Intervention: Intervention A: Training in communication skills and providing graphic feedback about glycosylated haemoglobin levels.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention B: Training in communication skills, providing graphic feedback about glycosylated haemoglobin levels, and additional telephone reinforcement.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: Usual care provided by General Practitioners.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including control): Secondary outcome measures include blood pressure, lipidemia, body mass index, and waist circumference.
Number of subjects: 0
Study: 21145258

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day plus placebo (ATV+PLA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day plus allopurinol 300 mg/day (ATV+ALLO)
Number of subjects: 74
Study: 20102063

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) as an irrigant
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 44
Study: 16773859

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment followed by treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment without assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive use of ineffective treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 15149789

Group type: EXPERIMENTAL
Intervention: Moderate exercise training (65-75% HRR, 25-30 min, 3 days/week for 10 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate exercise training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 27
Study: 11361264

Group type: EXPERIMENTAL
Intervention: Nimesulide alone (100 mg BD)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of nimesulide (100 mg) and cetirizine (10 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cetirizine alone (10 mg)
Number of subjects: 54
Study: 9164805

Group type: EXPERIMENTAL
Intervention: Group Well Child Care (GWCC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Individual Well Child Care (IWCC)
Number of subjects: 114
Study: 8395721

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg subcutaneously, administered 2 hours before surgery and each morning for 7 postoperative days (morning group)
Number of subjects: 10032

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg subcutaneously, administered the evening before surgery and postsurgically for 7 days in the evening (evening group)
Number of subjects: 10032

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 10032
Study: 3512282

Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional dose budesonide (400 micrograms per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms per day) during open-label phase
Number of subjects: 45
Study: 31327653

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29706321

Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 25341641

Group type: EXPERIMENTAL
Intervention: SHED-IT intervention
Number of subjects: 159
Study: 24427264

Group type: EXPERIMENTAL
Intervention: Community-based peer support intervention for exclusive breastfeeding, with peer supporters visiting women once antenatally and four times postpartum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operational 'non research' scenario for exclusive breastfeeding promotion.
Number of subjects: 0
Study: 22952175

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Corn-soya blend (CSB)
Number of subjects: 1125
Study: 18803247

Group type: EXPERIMENTAL
Intervention: High exposure (2126.8 microW/m(2)) and medium exposure (153.6 microW/m(2)) during sessions HM and MH
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low exposure (5.2 microW/m(2)) during scenario LL
Number of subjects: 57
Study: 18077994

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin plus bortezomib
Number of subjects: 646

Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 646
Study: 15366798

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine 0.8 mg/kg
Number of subjects: 60
Study: 11344193

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8033847

Group type: EXPERIMENTAL
Intervention: Methanol exposure at 200 ppm for 4 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (sham exposure)
Number of subjects: 26
Study: 2736882

Group type: EXPERIMENTAL
Intervention: Amino acid solution supplemented with L‐alanyl‐L‐glutamine (Ala‐Gln) and glycyl‐L‐tyrosine (Gly‐Tyr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control solution supplemented with alanine and glycine
Number of subjects: 6
Study: 4881071

Group type: EXPERIMENTAL
Intervention: Tetracycline (3 g or 4 g in one of 3 dose schedules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfaguanidine
Number of subjects: 0
Study: 31383649

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) administered as 3 monthly intravitreal injections followed by pro re nata at monthly visits
Number of subjects: 100
Study: 30222620

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 89
Study: 27780785

Group type: EXPERIMENTAL
Intervention: Goal ongoing (character continues to eat)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Goal completed (character completes eating)
Number of subjects: 147
Study: 26092310

Group type: EXPERIMENTAL
Intervention: Fully-liquid hexavalent vaccine (DTaP-IPV-HB-PRP-T, Sanofi Pasteur MSD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-fully liquid hexavalent vaccine (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fully-liquid hexavalent vaccine
Number of subjects: 96
Study: 23545009

Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy with one third of usual dose (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy with reduced dose and decreased number of instillations (two instead of three) (group II)
Number of subjects: 0
Study: 21756786

Group type: EXPERIMENTAL
Intervention: Food exchange serving based on glycemic load (FES + GL)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Food exchange serving (FES)
Number of subjects: 83
Study: 19325013

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 9
Study: 17118319

Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: PPI preplan
Number of subjects: 126

Group type: COMPARATOR
Intervention: PPI postplan
Number of subjects: 126
Study: 12752845

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 11118822

Group type: EXPERIMENTAL
Intervention: Essential amino acid (EAA) supplementation (average daily dose of 18.3 g of EAAs in pill form)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 21
Study: 9146772

Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (1 g)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Hydrocortisone foam (100 mg)
Number of subjects: 242
Study: 7816790

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) for acute treatment, 200 mg at first symptoms, repeat after 2-3 hours if needed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) for prophylactic treatment, 300 mg sustained release or 100 mg 3 times daily.
Number of subjects: 0
Study: 2905992

Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg once daily for 6 weeks
Number of subjects: 15
Study: 29380267

Group type: COMPARATOR
Intervention: SUVN-502 200 mg single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: SUVN-502 130 mg once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: SUVN-502 100 mg once daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SUVN-502 100 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SUVN-502 50 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SUVN-502 50 mg and 100 mg once daily
Number of subjects: 0
Study: 27733377

Group type: COMPARATOR
Intervention: mFOLFOX-6
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: RAM+mFOLFOX-6
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: ICR+mFOLFOX-6
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 158
Study: 25182248

Group type: EXPERIMENTAL
Intervention: High-intensity rosuvastatin (40 mg/day) for 13 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 103
Study: 23465742

Group type: EXPERIMENTAL
Intervention: LHRHa
Number of subjects: 254

Group type: COMPARATOR
Intervention: Oestrogen patches
Number of subjects: 254
Study: 21270200

Group type: EXPERIMENTAL
Intervention: Normal ABI (0.91-1.3)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Low ABI (<0.9)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: High ABI (>1.3)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Noncompressible artery (NC)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Low ABI
Number of subjects: 2240

Group type: COMPARATOR
Intervention: High ABI
Number of subjects: 2240
Study: 18434900

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy for strict blood glucose control to normoglycemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 16549920

Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 12517741

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at doses of 25, 50, 125, 300, or 600 mg/wk for 20 weeks
Number of subjects: 54
Study: 10719857

Group type: EXPERIMENTAL
Intervention: Intrathecal bolus injections of baclofen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous administration of baclofen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study: 9175128

Group type: EXPERIMENTAL
Intervention: Patients with left or right hemisphere infarctions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 8357287

Group type: EXPERIMENTAL
Intervention: Inpatient interdisciplinary geriatric consultation
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (no geriatric consultation)
Number of subjects: 197
Study: 3542445

Group type: COMPARATOR
Intervention: Acarbose 400 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Acarbose 200 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Acarbose 100 mg (after one week of administration)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Acarbose (all doses tested)
Number of subjects: 5
Study: 28669329

Group type: EXPERIMENTAL
Intervention: 5 mg/day rosuvastatin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20-40 mg/day rosuvastatin
Number of subjects: 40
Study: 27609386

Group type: EXPERIMENTAL
Intervention: Easy One Adper (A1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Adper Easy One (B1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: iBond SE (C1)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Phosphoric acid etching (A2, B2, C2)
Number of subjects: 360
Study: 23999037

Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine combination (20/5mg)
Number of subjects: 276
Study: 22417131

Group type: EXPERIMENTAL
Intervention: Intensive long-term step-down treatment program (short-term day hospital treatment followed by combined group and individual psychotherapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy in private practice
Number of subjects: 113
Study: 20171677

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 220
Study: 18242805

Group type: EXPERIMENTAL
Intervention: Knee-bracing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ankle-bracing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unbraced (normative data)
Number of subjects: 10
Study: 16287075

Group type: EXPERIMENTAL
Intervention: HPV testing as a primary cervical cancer screening test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12966418

Group type: EXPERIMENTAL
Intervention: Supportive care (SC) with concomitant chemotherapy
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Supportive care (SC) with corticosteroids
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Supportive care (SC) for elderly patients
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Supportive care (SC) overall
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Cisplatin-based treatment
Number of subjects: 1185
Study: 11135780

Group type: EXPERIMENTAL
Intervention: Morning examination (n = 6483)
Number of subjects: 12882

Group type: COMPARATOR
Intervention: Afternoon examination (n = 6399)
Number of subjects: 12882
Study: 8787869

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given orally (500 mg) alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ciprofloxacin given orally (500 mg) plus enteral feeding (Sustacal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given via gastrostomy tube (500 mg crushed in 60 ml water)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ciprofloxacin given via gastrostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given via jejunostomy tube (500 mg crushed)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ciprofloxacin given via jejunostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Number of subjects: 26
Study: 1454432

Group type: EXPERIMENTAL
Intervention: Cefixime (CFX), 8 mg/kg once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Penicillin V (PEN), 250 mg 3 times daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cefixime (CFX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Penicillin V (PEN)
Number of subjects: 110
Study: 3906248

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 600 mg daily for six months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study: 31923203

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (educational handouts)
Number of subjects: 6082

Group type: EXPERIMENTAL
Intervention: Behavioral intervention + recliner chair
Number of subjects: 6082

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6082
Study: 30204953

Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CPPs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Liquid-stored platelets (LSPs)
Number of subjects: 28